UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2024
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware13-5315170
(State of Incorporation)(I.R.S. Employer Identification No.)
66 Hudson Boulevard East, New York, New York 10001-2192
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.05 par valuePFENew York Stock Exchange
1.000% Notes due 2027PFE27New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
YesxNo
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
YesxNo
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:
Large Accelerated filer x Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes Nox
At May 3, 2024, 5,666,592,898 shares of the issuer s voting common stock were outstanding.
TABLE OF CONTENTS
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Income
Condensed Consolidated Statements of Comprehensive Income
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements of Equity
Condensed Consolidated Statements of Cash Flows
Notes to Condensed Consolidated Financial Statements
10
Item 2.
Management s Discussion and Analysis of Financial Condition and Results of Operations
36
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
54
Item 4.
Controls and Procedures
54
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
54
Item 1A.
Risk Factors
54
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
54
Item 3.
Defaults Upon Senior SecuritiesN/A
Item 4.
Mine Safety DisclosuresN/A
Item 5.
Other Information54
Item 6.
Exhibits
55
Signature
55
N/A = Not Applicable
DEFINED TERMS
Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three months ended February 25, 2024 and February 26, 2023, and for U.S. subsidiaries is as of and for the three months ended March 31, 2024 and April 2, 2023. References to Notes in this Form 10-Q are to the Notes to the Condensed or Consolidated Financial Statements in this Form 10-Q or in our 2023 Form 10-K. We also have used several other terms in this Form 10-Q, most of which are explained or defined below:
2023 Form 10-K
Annual Report on Form 10-K for the fiscal year ended December 31, 2023
ALKanaplastic lymphoma kinase
Alliance revenuesRevenues from alliance agreements under which we co-promote products discovered or developed by other companies or us
AstellasAstellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.
ATTR-CMtransthyretin amyloid cardiomyopathy
BiohavenBiohaven Pharmaceutical Holding Company Limited
BioNTechBioNTech SE
BiopharmaGlobal Biopharmaceuticals Business
BMSBristol-Myers Squibb Company
BODBoard of Directors
CDCU.S. Centers for Disease Control and Prevention
Comirnaty*Unless otherwise noted, refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine; Comirnaty (COVID-19 Vaccine, mRNA) original monovalent formula; the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5); the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula); Comirnaty (COVID-19 Vaccine, mRNA) 2023-2024 Formula; Comirnaty Original/Omicron BA.1; Comirnaty Original/Omicron BA.4/BA.5; and Comirnaty Omicron XBB.1.5.
COVID-19novel coronavirus disease of 2019
Developed MarketsIncludes, but is not limited to, the following markets: Western Europe, Japan, Central Europe, Canada, Scandinavian countries, Australia, South Korea, New Zealand, the Balkans and Finland
EMAEuropean Medicines Agency
Emerging MarketsIncludes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, the Middle East, Eastern Europe (excluding the Balkans) and Turkey
EPS
earnings per share
ESGEnvironmental, Social and Governance
EUEuropean Union
EUAemergency use authorization
Exchange ActSecurities Exchange Act of 1934, as amended
FASBFinancial Accounting Standards Board
FDAU.S. Food and Drug Administration
Form 10-QThis Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024
GAAPGenerally Accepted Accounting Principles
GBTGlobal Blood Therapeutics, Inc.
GSKGSK plc
HaleonHaleon plc
HIPAAHealth Insurance Portability and Accountability Act of 1996
HospiraHospira, Inc.
HRR
homologous recombination repair
IPR&Din-process research and development
IRAInflation Reduction Act of 2022
IRSU.S. Internal Revenue Service
JVjoint venture
KingKing Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)
LOEloss of exclusivity
mCRCmetastatic colorectal cancer
mCRPCmetastatic castration-resistant prostate cancer
mCSPCmetastatic castration-sensitive prostate cancer
MD&AManagement s Discussion and Analysis of Financial Condition and Results of Operations
MDLMulti-District Litigation
MeridianMeridian Medical Technologies, Inc.
Moody sMoody s Investors Service
mRNAmessenger ribonucleic acid
MylanMylan N.V.
NDA
New Drug Application
NimbusNimbus Therapeutics, LLC
nmCRPCnon-metastatic castration-resistant prostate cancer
nmCSPC
non-metastatic castration-sensitive prostate cancer
NSCLCnon-small cell lung cancer
ODToral disintegrating tablet
ORD
Oncology Research and Development
OTCover-the-counter
Paxlovid*an oral COVID-19 treatment (nirmatrelvir tablets and ritonavir tablets)
PC1Pfizer CentreOne
PharmaciaPharmacia LLC (formerly Pharmacia Corporation)
PP&E
Property, plant and equipment
PRD
Pfizer Research and Development
Prevnar familyIncludes Prevnar 20/Apexxnar (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult)
PsApsoriatic arthritis
RArheumatoid arthritis
RCCrenal cell carcinoma
R&Dresearch and development
RSVrespiratory syncytial virus
S&PStandard & Poor s
SeagenSeagen Inc. and its subsidiaries
SECU.S. Securities and Exchange Commission
Takeda
Takeda Pharmaceutical Company Limited
UCulcerative colitis
U.K.United Kingdom
Upjohn BusinessPfizer s former global, primarily off-patent branded and generics business, which included a portfolio of 20 globally recognized solid oral dose brands, including Lipitor, Lyrica, Norvasc, Celebrex and Viagra, as well as a U.S.-based generics platform, Greenstone, that was spun-off on November 16, 2020 and combined with Mylan to create Viatris
U.S.United States
ViatrisViatris Inc.
ViiVViiV Healthcare Limited
Vyndaqel familyIncludes Vyndaqel, Vyndamax and Vynmac
*The Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) and certain uses of Paxlovid have not been approved or licensed by the FDA. The Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) has been authorized for emergency use by the FDA under an EUA to prevent COVID-19 in individuals aged 6 months through 11 years of age. Paxlovid has been authorized for emergency use by the FDA under an EUA for the treatment of mild-to-moderate COVID-19 in pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product during the COVID-19 pandemic under Section 564(b)(1) of the U.S. Federal Food, Drug and Cosmetics Act, unless the declaration is terminated or authorization revoked sooner. Please see the EUA Fact Sheets at www.covid19oralrx.com and www.cvdvaccine-us.com.
This Form 10-Q includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or efficacy of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.
Some amounts in this Form 10-Q may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their owners.
The information contained on our website, our Facebook, Instagram, YouTube and LinkedIn pages or our X (formerly known as Twitter) accounts, or any third-party website, is not incorporated by reference into this Form 10-Q.
Certain of the products and product candidates discussed in this Form 10-Q are being co-researched, co-developed and/or co-promoted in collaboration with other companies for which Pfizer s rights vary by market or are the subject of agreements pursuant to which Pfizer has commercialization rights in certain markets.
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
(MILLIONS, EXCEPT PER SHARE DATA)March 31,
2024April 2,
2023
Revenues:
Product revenues(a)
$12,443 $16,221
Alliance revenues(a)
2,172 2,060
Royalty revenues(a)
263 204
Total revenues
14,879 18,486
Costs and expenses:
Cost of sales(b)
3,379 4,886
Selling, informational and administrative expenses(b)
3,495 3,418
Research and development expenses(b)
2,493 2,505
Acquired in-process research and development expenses 21
Amortization of intangible assets1,308 1,103
Restructuring charges and certain acquisition-related costs102 9
Other (income)/deductions net680 275
Income from continuing operations before provision/(benefit) for taxes on income
3,421 6,270
Provision/(benefit) for taxes on income
293 715
Income from continuing operations
3,128 5,555
Discontinued operations net of tax(5)1
Net income before allocation to noncontrolling interests
3,123 5,556
Less: Net income attributable to noncontrolling interests8 13
Net income attributable to Pfizer Inc. common shareholders
$3,115 $5,543
Earnings per common share basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders$0.55 $0.98
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
$0.55 $0.98
Earnings per common share diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders$0.55 $0.97
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
$0.55 $0.97
Weighted-average shares basic5,657 5,634
Weighted-average shares diluted5,697 5,727
(a)See Note 1A.
(b)Exclusive of amortization of intangible assets.
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months Ended
(MILLIONS)March 31,
2024April 2,
2023
Net income before allocation to noncontrolling interests
$3,123 $5,556
Foreign currency translation adjustments, net140 101
Unrealized holding gains/(losses) on derivative financial instruments, net217 2
Reclassification adjustments for (gains)/losses included in net income(a)
(12)303
205 305
Unrealized holding gains/(losses) on available-for-sale securities, net(51)87
Reclassification adjustments for (gains)/losses included in net income(b)
(14)(509)
(65)(422)
Reclassification adjustments related to amortization of prior service costs and other, net(28)(30)
Reclassification adjustments related to curtailments of prior service costs and other, net (5)
(28)(35)
Other comprehensive income/(loss), before tax251 (50)
Tax provision/(benefit) on other comprehensive income/(loss)53 (63)
Other comprehensive income/(loss) before allocation to noncontrolling interests$198 $12
Comprehensive income/(loss) before allocation to noncontrolling interests$3,321 $5,569
Less: Comprehensive income/(loss) attributable to noncontrolling interests3 10
Comprehensive income/(loss) attributable to Pfizer Inc.$3,319 $5,558
(a)Reclassified into Other (income)/deductions net and Cost of sales. See Note 7E.
(b)Reclassified into Other (income)/deductions net.
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS)March 31,
2024December 31, 2023
(Unaudited)
Assets
Cash and cash equivalents$719 $2,853
Short-term investments11,209 9,837
Trade accounts receivable, less allowance for doubtful accounts: 2024 $479; 2023 $470
10,989 11,566
Inventories10,892 10,189
Current tax assets4,233 3,978
Other current assets4,372 4,911
Total current assets42,415 43,333
Equity-method investments8,123 11,637
Long-term investments3,490 3,731
Property, plant and equipment, less accumulated depreciation: 2024 $16,362; 2023 $16,045
18,803 18,940
Identifiable intangible assets62,829 64,900
Goodwill69,297 67,783
Noncurrent deferred tax assets and other noncurrent tax assets4,942 3,706
Other noncurrent assets11,197 12,471
Total assets$221,095 $226,501
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2024 $1,001; 2023 $2,254
$8,232 $10,350
Trade accounts payable5,591 6,710
Dividends payable 2,372
Income taxes payable3,192 2,349
Accrued compensation and related items2,192 2,776
Deferred revenues2,502 2,700
Other current liabilities18,788 20,537
Total current liabilities40,497 47,794
Long-term debt61,307 61,538
Pension and postretirement benefit obligations2,076 2,167
Noncurrent deferred tax liabilities931 640
Other taxes payable8,603 8,534
Other noncurrent liabilities15,122 16,539
Total liabilities128,537 137,213
Commitments and Contingencies
Common stock480 478
Additional paid-in capital92,997 92,631
Treasury stock(114,755)(114,487)
Retained earnings121,318 118,353
Accumulated other comprehensive loss(7,758)(7,961)
Total Pfizer Inc. shareholders equity92,282 89,014
Equity attributable to noncontrolling interests276 274
Total equity92,558 89,288
Total liabilities and equity$221,095 $226,501
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(UNAUDITED)
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l
Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.
LossShare-
holders EquityNon-controlling interestsTotal Equity
Balance, January 1, 20249,562 $478 $92,631 (3,916)$(114,487)$118,353 $(7,961)$89,014 $274 $89,288
Net income
3,115 3,115 8 3,123
Other comprehensive income/(loss), net of tax203 203 (5)198
Cash dividends declared, per share: $
Common stock
Share-based payment transactions30 1 366 (10)(268)(151)(51)(51)
Other
Balance, March 31, 20249,592 $480 $92,997 (3,925)$(114,755)$121,318 $(7,758)$92,282 $276 $92,558
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l
Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.
LossShare-
holders EquityNon-controlling interestsTotal Equity
Balance, January 1, 20239,519 $476 $91,802 (3,903)$(113,969)$125,656 $(8,304)$95,661 $256 $95,916
Net income
5,543 5,543 13 5,556
Other comprehensive income/(loss), net of tax15 15 (3)12
Cash dividends declared, per share: $
Common stock
Share-based payment transactions41 2 350 (12)(504)(97)(249)(249)
Other
Balance, April 2, 20239,560 $478 $92,153 (3,915)$(114,473)$131,102 $(8,289)$100,970 $266 $101,236
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Three Months Ended
(MILLIONS)March 31,
2024April 2,
2023
Operating Activities
Net income before allocation to noncontrolling interests$3,123 $5,556
Discontinued operations net of tax(5)1
Net income from continuing operations before allocation to noncontrolling interests3,128 5,555
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by/(used in) operating activities:
Depreciation and amortization1,736 1,487
Asset write-offs and impairments136 270
Deferred taxes(441)(598)
Share-based compensation expense220 105
Benefit plan contributions in excess of expense/income(201)(200)
Other adjustments, net(151)99
Other changes in assets and liabilities, net of acquisitions and divestitures(3,336)(5,507)
Net cash provided by/(used in) operating activities1,090 1,212
Investing Activities
Purchases of property, plant and equipment(704)(1,139)
Purchases of short-term investments(797)(6,665)
Proceeds from redemptions/sales of short-term investments658 6,400
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less(1,187)4,665
Purchases of long-term investments(35)(51)
Proceeds from redemptions/sales of long-term investments305 124
Proceeds from partial sale of investment in Haleon(a)
3,491
Other investing activities, net (18)
Net cash provided by/(used in) investing activities1,732 3,315
Financing Activities
Proceeds from short-term borrowings1,444 11
Payments on short-term borrowings(328)
Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less
(2,039)226
Payments on long-term debt(1,250)(269)
Cash dividends paid(2,372)(2,303)
Other financing activities, net(386)(436)
Net cash provided by/(used in) financing activities(4,931)(2,771)
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents
(28)(2)
Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents(2,137)1,754
Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period2,917 468
Cash and cash equivalents and restricted cash and cash equivalents, at end of period$780 $2,222
Supplemental Cash Flow Information
Cash paid during the period for:
Income taxes
$184 $329
Interest paid
415 419
Interest rate hedges33 60
(a) See Note 2B.
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of Presentation and Significant Accounting Policies
A. Basis of Presentation
We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2023 Form 10-K. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.
These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2023 Form 10-K. Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three months ended February 25, 2024 and February 26, 2023, and for U.S. subsidiaries is as of and for the three months ended March 31, 2024 and April 2, 2023.
We manage our commercial operations through two operating segments, each led by a single manager: Biopharma and Business Innovation. Biopharma is the only reportable segment. See Note 13A.
We have made certain reclassification adjustments to conform prior-period amounts to the current presentation for:
in the first quarter of 2024, we reclassified royalty income (substantially all of which is related to Biopharma) from Other (income)/deductions net and began presenting Royalty revenues as a separate line item within Total revenues in our consolidated statements of income, and reclassified the associated royalty receivables from Other current assets to Trade accounts receivable, less allowance for doubtful accounts in our consolidated balance sheet;
in the fourth quarter of 2023, we began presenting Product revenues and Alliance revenues as separate line items within Total revenues in our consolidated statements of income; and
segment reporting and geographic information in connection with the commercial reorganization that went into effect on January 1, 2024 (see Note 13).
Business development activities, including the December 2023 acquisition of Seagen, impacted financial results in the periods presented. See Note 2 below, as well as Notes 1A and 2 in our 2023 Form 10-K.
B. New Accounting Standard Adopted in 2024
On January 1, 2024, we adopted a new accounting standard which clarifies that contractual sale restrictions are not considered in measuring equity securities at fair value. The new guidance is consistent with our existing policy; therefore, it had no impact on our consolidated financial statements.
C. Revenues and Trade Accounts Receivable
Customers Our prescription biopharmaceutical products, with the exception of Paxlovid in 2023, are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. We principally sold Paxlovid globally to government agencies in 2023. Our vaccines in the U.S. are primarily sold directly to the federal government (including the CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery systems. Our vaccines outside the U.S. are primarily sold to government and non-government institutions. Certain of our vaccines, including Comirnaty, are subject to seasonality of demand.
Deductions from Revenues Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:
(MILLIONS)March 31,
2024December 31, 2023
Reserve against Trade accounts receivable, less allowance for doubtful accounts
$1,573 $1,770
Other current liabilities:
Accrued rebates5,880 5,546
Other accruals646 902
Other noncurrent liabilities
382 796
Total accrued rebates and other sales-related accruals$8,481 $9,014
Trade Accounts Receivable Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience,
10
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables.
In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded.
During the three months ended March 31, 2024 and April 2, 2023, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements. For additional information on our trade accounts receivable, see Note 1G in our 2023 Form 10-K.
Note 2. Acquisition and Equity-Method Investment
A. Acquisition
Seagen On December 14, 2023 (the acquisition date), we acquired Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 per share in cash. The total fair value of the consideration transferred was $44.2 billion ($43.4 billion, net of cash acquired). The combination of certain Pfizer and Seagen entities may be pending in various jurisdictions and integration is subject to completion of various local legal and regulatory steps.
The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date, including adjustments made in the first quarter of 2024 (measurement period adjustments) with a corresponding change to goodwill. The estimated values are not yet finalized (see below) and are subject to change, which could be significant. We will finalize the amounts recognized as soon as possible but no later than one year from the acquisition date.
(MILLIONS)Amounts Recognized
as of Acquisition Date
(as previously reported as of December 31, 2023)
Measurement Period Adjustments(a)
Amounts Recognized as of Acquisition Date (as adjusted)
Working capital, excluding inventories
$736 $(159)$577
Inventories(b)
4,195 (891)3,304
Property, plant and equipment524 (239)285
Identifiable intangible assets, excluding in-process research and development(c)
7,970 (560)7,410
In-process research and development20,800 (100)20,700
Other noncurrent assets174 (94)80
Net income tax accounts
(6,123)468 (5,655)
Other noncurrent liabilities(167)51 (116)
Total identifiable net assets28,108 (1,524)26,584
Goodwill16,126 1,524 17,650
Net assets acquired/total consideration transferred$44,234 $ $44,234
(a)The changes in the estimated fair values are primarily to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date.
(b)As adjusted, comprised of $1.2 billion current inventories and $2.1 billion noncurrent inventories.
(c)As adjusted, comprised mainly of $7.0 billion of finite-lived developed technology rights with an estimated weighted-average life of approximately 18 years.
The measurement period adjustments did not have a material impact on our earnings.
The following items are subject to change:
Amounts for certain balances included in working capital (excluding inventories), and certain legal contingencies, pending receipt of certain information that could affect provisional amounts recorded. We do not believe any adjustments for legal contingencies will have a material impact on our consolidated financial statements.
Amounts for identifiable intangible assets, inventories, contractual commitments, PP&E, and operating lease right-of-use assets and liabilities, pending finalization of valuation efforts, the completion of certain physical inventory counts and the confirmation of the physical existence and condition of certain PP&E assets.
11
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Amounts for income tax assets, receivables and liabilities, pending the filing of Seagen s pre-acquisition tax returns and the receipt of information, including but not limited to that from taxing authorities, which may change certain estimates and assumptions used.
The following table provides unaudited U.S. GAAP supplemental pro forma information as if the acquisition of Seagen had occurred on January 1, 2022:
Unaudited Supplemental Pro Forma Consolidated Results
Three Months Ended
(MILLIONS, EXCEPT PER SHARE DATA)April 2,
2023
Revenues$19,006
Net income attributable to Pfizer Inc. common shareholders
4,651
Diluted earnings per share attributable to Pfizer Inc. common shareholders
0.81
The unaudited supplemental pro forma consolidated results do not purport to reflect what the combined company s results of operations would have been had the acquisition occurred on January 1, 2022, nor do they project the future results of operations of the combined company or reflect the expected realization of any cost savings associated with the acquisition. The actual results of operations of the combined company may differ significantly from the pro forma adjustments reflected here due to many factors.
The unaudited supplemental pro forma financial information includes various assumptions, including those related to the preliminary purchase price allocation of the assets acquired and the liabilities assumed from Seagen. The historical U.S. GAAP financial information of Pfizer and Seagen was adjusted, primarily for the following pre-tax adjustments for the three months ended April 2, 2023:
Additional amortization expense of approximately $142 million related to the preliminary estimate of the fair value of identifiable intangible assets acquired.
Additional expense related to the preliminary estimate of the fair value adjustment to acquisition-date inventory estimated to have been sold of approximately $224 million.
Additional estimated interest expense of approximately $488 million related to the debt issued by Pfizer and the commercial paper borrowings to partially finance the acquisition.
Elimination of interest income of approximately $67 million associated with money market funds under the assumption that a portion of these funds would have been liquidated to partially fund the acquisition.
The above adjustments were then adjusted for the applicable tax impact using an estimated weighted-average statutory tax rate applied to the applicable pro forma adjustments.
B. Equity-Method Investment
Haleon We owned 32% of Haleon as of December 31, 2023. In March 2024, we sold approximately 30% of our investment in Haleon through the sale of 791 million ordinary shares in a global public offering, and the sale of 102 million ordinary shares directly to Haleon for total consideration of $3.5 billion. We recognized a gain on the sale of our Haleon shares of $150 million during the first quarter of 2024 in Other (income)/deductions net (see Note 4). After the share sale, we owned approximately 23% of the outstanding voting shares of Haleon as of March 31, 2024.
The fair value of our investment in Haleon as of March 31, 2024, based on quoted market prices of Haleon stock, was $8.7 billion. Haleon is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in other comprehensive income. We record our share of earnings from Haleon on a quarterly basis on a one-quarter lag in Other (income)/deductions net.
12
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
The following table summarizes the change in the carrying value of our investment in Haleon:
Three Months Ended
(MILLIONS)March 31,
2024April 2,
2023
Beginning carrying value reported in Equity-method investments
$11,451 $10,824
Carrying value of shares sold
(3,312)
Currency translation adjustments and other(a)
(132)89
Basis difference adjustments and amortization(b)
(100)
Pfizer share of Haleon earnings
15 68
Ending carrying value reported in Equity-method investments
$7,922 $10,980
(a)See Note 6.
(b)Equity-method basis difference adjustments and amortization included in Other (income)/deductions net. Adjustments are associated with the impact of Haleon s brand sales and impairments of intangible assets and changes in Haleon s tax rates on intangible asset-related deferred tax liabilities. See Note 4.
Summarized financial information for Haleon for the three months ending December 31, 2023, the most recent period available, and for the three months ending December 31, 2022, is as follows:
Three Months Ended
(MILLIONS)December 31,
2023December 31,
2022
Net sales$3,434 $3,261
Cost of sales(1,596)(1,496)
Gross profit$1,837 $1,766
Income from continuing operations60 225
Net income60 225
Income attributable to shareholders47 211
Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
A. Realigning our Cost Base Program
In the fourth quarter of 2023, we announced that we launched a multi-year, enterprise-wide cost realignment program that aims to realign our costs with our longer-term revenue expectations. We expect costs associated with this multi-year effort to continue through 2024 and to total approximately $2.8 billion, primarily representing cash expenditures for severance and implementation costs, of which $2.3 billion is associated with our Biopharma segment. From the start of this program through March 31, 2024, we incurred costs under this program of $1.6 billion, of which $1.3 billion is associated with our Biopharma segment (substantially all of which represents restructuring charges).
13
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
B. Key Activities
The following summarizes costs and credits for acquisitions and cost-reduction/productivity initiatives:
Three Months Ended
(MILLIONS)March 31,
2024April 2,
2023
Restructuring charges/(credits):
Employee terminations$(29)$(36)
Asset impairments25 (10)
Exit costs
14 2
Restructuring charges/(credits)(a)
10 (44)
Transaction costs(b)
Integration costs and other(c)
87 52
Restructuring charges and certain acquisition-related costs102 9
Net periodic benefit costs/(credits) recorded in Other (income)/deductions net
3 (5)
Additional depreciation asset restructuring recorded in our condensed consolidated statements of income, mainly in Cost of sales(d)
4 18
Implementation costs recorded in our condensed consolidated statements of income as follows(e):
Cost of sales16 15
Selling, informational and administrative expenses29 59
Research and development expenses13 11
Total implementation costs58 85
Total costs associated with acquisitions and cost-reduction/productivity initiatives$168 $107
(a)In 2024, primarily represents Seagen acquisition-related costs, largely offset by cost-reduction initiatives. In 2023, primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: credits of $37 million for the three months ended March 31, 2024 and credits of $64 million for the three months ended April 2, 2023.
(b)Represents external costs for banking, legal, accounting and other similar services.
(c)Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.
(d)Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
(e)Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
The Biopharma segment information above reflects changes as a result of the reorganization in the first quarter of 2024 (see Note 13A).
The following summarizes the components and changes in restructuring accruals:
(MILLIONS)Employee
Termination
CostsAsset
Impairment
ChargesExit CostsAccrual
Balance, December 31, 2023(a)
$1,978 $ $11 $1,988
Provision/(credit)(29)25 14 10
Utilization and other(b)
(320)(25)(15)(360)
Balance, March 31, 2024(c)
$1,628 $ $10 $1,638
(a)Included in Other current liabilities ($1.3 billion) and Other noncurrent liabilities ($663 million).
(b)Other activity includes adjustments for foreign currency translation that are not material to our condensed consolidated financial statements.
(c)Included in Other current liabilities ($1.1 billion) and Other noncurrent liabilities ($519 million).
14
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 4. Other (Income)/Deductions Net
Components of Other (income)/deductions net include:
Three Months Ended
(MILLIONS)March 31,
2024April 2,
2023
Interest income$(129)$(177)
Interest expense790 318
Net interest expense(a)
661 141
Net (gains)/losses recognized during the period on equity securities(b)
(25)451
Income from collaborations, out-licensing arrangements and sales of compound/product rights (68)
Net periodic benefit costs/(credits) other than service costs(103)(80)
Certain legal matters, net(c)
208 36
Certain asset impairments(d)
109 264
Haleon equity method (income)/loss(e)
88 (68)
Other, net(f)
(258)(403)
Other (income)/deductions net$680 $275
(a)The increase in net interest expense in the first quarter of 2024 reflects (i) higher interest expense driven by our $31 billion aggregate principal amount of senior unsecured notes issued in May 2023, as well as $8 billion of commercial paper issued in the fourth quarter of 2023 as part of the financing for our acquisition of Seagen and (ii) a decrease in interest income due to lower investment balances after completion of our $43.4 billion Seagen acquisition in December 2023.
(b)The net losses in the first quarter of 2023 include, among other things, unrealized losses of $363 million related to our investments in Cerevel Therapeutics Holdings, Inc. and BioNTech.
(c)The first quarters of 2024 and 2023 primarily include certain product liability expenses related to products discontinued and/or divested by Pfizer.
(d)The first quarter of 2024 represents intangible asset impairment charges associated with our Biopharma segment for developed technology rights due to updated commercial forecasts mainly reflecting competitive pressures. The first quarter of 2023 primarily represented intangible asset impairment charges, including $128 million associated with Other business activities, related to IPR&D and developed technology rights for acquired software assets and reflected unfavorable pivotal trial results and updated commercial forecasts, and $120 million associated with our Biopharma segment resulting from the discontinuation of a study related to an out-licensed IPR&D asset for the treatment of prostate cancer.
(e)See Note 2B.
(f)The first quarter of 2024 primarily includes, among other things, a $150 million gain on the partial sale of our investment in Haleon and dividend income of $61 million from our investment in ViiV. The first quarter of 2023 primarily included, among other things, dividend income of $211 million from our investment in Nimbus resulting from Takeda s acquisition of Nimbus s oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor program subsidiary, and $92 million from our investment in ViiV.
Additional information about the intangible assets that were impaired during 2024 follows:
Three Months Ended
Fair Value(a)
March 31, 2024
(MILLIONS)AmountLevel 1Level 2Level 3Impairment
Intangible assets Developed technology rights(b)
$102 $ $ $102 $109
(a)The fair value amount is presented as of the date of impairment, as this asset is not measured at fair value on a recurring basis. See also Note 1E in our 2023 Form 10-K.
(b)Reflects intangible assets written down to fair value in 2024. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.
Note 5. Tax Matters
A. Taxes on Income from Continuing Operations
Our effective tax rate for continuing operations was 8.6% for the first quarter of 2024, compared to 11.4% for the first quarter of 2023. The decrease in the effective tax rate for the first quarter of 2024, compared to the first quarter of 2023, was primarily due to a favorable change in the jurisdictional mix of earnings.
We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings over eight years through 2026. The sixth annual installment was paid by its April 15, 2024 due date and is reported in current Income taxes payable as of March 31, 2024. The remaining liability is reported in noncurrent Other taxes payable. Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.
15
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
For the year ended December 31, 2023, our cash paid for income taxes, net of refunds, was $3.1 billion, of which $1.9 billion was paid in the U.S.
B. Tax Contingencies
We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation.
The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. With respect to Pfizer, tax years 2016-2018 are under audit. Tax years 2019-2024 are open but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years and certain related audits, appeals and investigations in certain major international tax jurisdictions dating back to 2012.
See Note 5D in our 2023 Form 10-K.
C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)
Components of Tax provision/(benefit) on other comprehensive income/(loss) include:
Three Months Ended
(MILLIONS)March 31,
2024April 2,
2023
Foreign currency translation adjustments, net(a)
$25 $(25)
Unrealized holding gains/(losses) on derivative financial instruments, net45 3
Reclassification adjustments for (gains)/losses included in net income
(4)21
41 24
Unrealized holding gains/(losses) on available-for-sale securities, net(6)11
Reclassification adjustments for (gains)/losses included in net income
(2)(64)
(8)(53)
Reclassification adjustments related to amortization of prior service costs and other, net(5)(7)
Reclassification adjustments related to curtailments of prior service costs and other, net (1)
(5)(9)
Tax provision/(benefit) on other comprehensive income/(loss)$53 $(63)
(a)Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.
Note 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests
The following summarizes the changes, net of tax, in Accumulated other comprehensive loss:
Net Unrealized Gains/(Losses)Benefit Plans
(MILLIONS)Foreign Currency Translation Adjustments(a)
Derivative Financial InstrumentsAvailable-For-Sale SecuritiesPrior Service (Costs)/Credits and OtherAccumulated Other Comprehensive Income/(Loss)
Balance, December 31, 2023
$(7,863)$(217)$(9)$128 $(7,961)
Other comprehensive income/(loss)(b)
120 164 (57)(24)203
Balance, March 31, 2024$(7,743)$(53)$(66)$104 $(7,758)
(a)Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests.
(b)Foreign currency translation adjustments include net gains related to the impact of our net investment hedging program and net losses related to our equity-method investment in Haleon (see Note 2B).
16
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 7. Financial Instruments
A. Fair Value Measurements
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:
March 31, 2024December 31, 2023
(MILLIONS)TotalLevel 1Level 2TotalLevel 1Level 2
Financial assets:
Short-term investments
Equity securities with readily determinable fair values:
Money market funds$2,483 $ $2,483 $5,124 $ $5,124
Available-for-sale debt securities:
Government and agency non-U.S.
5,214 5,214 817 817
Government and agency U.S.
1,958 1,958 2,601 2,601
Corporate and other
1,045 1,045 982 982
8,217 8,217 4,400 4,400
Total short-term investments10,700 10,700 9,524 9,524
Other current assets
Derivative assets:
Interest rate contracts
1 1
Foreign exchange contracts
390 390 298 298
Total other current assets391 391 298 298
Long-term investments
Equity securities with readily determinable fair values(a)
2,543 2,542 2,779 2,772 7
Available-for-sale debt securities:
Government and agency non-U.S.
131 131 124 124
Corporate and other
6 6 26 26
137 137 150 150
Total long-term investments2,680 2,542 138 2,929 2,772 156
Other noncurrent assets
Derivative assets:
Interest rate contracts
26 26 144 144
Foreign exchange contracts
364 364 258 258
Total derivative assets390 390 402 402
Insurance contracts(b)
853 853 790 790
Total other noncurrent assets1,243 1,243 1,191 1,191
Total assets$15,013 $2,542 $12,471 $13,943 $2,772 $11,170
Financial liabilities:
Other current liabilities
Derivative liabilities:
Interest rate contracts$17 $ $17 $16 $ $16
Foreign exchange contracts
117 117 404 404
Total other current liabilities134 134 420 420
Other noncurrent liabilities
Derivative liabilities:
Interest rate contracts346 346 275 275
Foreign exchange contracts
665 665 725 725
Total other noncurrent liabilities1,011 1,011 1,000 1,000
Total liabilities$1,146 $ $1,146 $1,420 $ $1,420
(a)Long-term equity securities of $115 million as of March 31, 2024 and $130 million as of December 31, 2023 were held in restricted trusts for U.S. non-qualified employee benefit plans.
(b)Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions net (see Note 4).
Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis The carrying value of Long-term debt, excluding the current portion, was $61 billion as of March 31, 2024 and $62 billion as of December 31, 2023. The estimated fair value of such debt, using a market approach and Level 2 inputs, was $60 billion as of March 31, 2024 and $61 billion as of December 31, 2023.
The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant
17
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
as of March 31, 2024 and December 31, 2023. The fair value measurements of our held-to-maturity debt securities and short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.
B. Investments
Total Short-Term, Long-Term and Equity-Method Investments
The following summarizes our investments by classification type:
(MILLIONS)March 31,
2024 December 31, 2023
Short-term investments
Equity securities with readily determinable fair values(a)
$2,483 $5,124
Available-for-sale debt securities8,217 4,400
Held-to-maturity debt securities510 313
Total Short-term investments$11,209 $9,837
Long-term investments
Equity securities with readily determinable fair values(b)
$2,543 $2,779
Available-for-sale debt securities137 150
Held-to-maturity debt securities45 47
Private equity securities at cost(b)
765 755
Total Long-term investments$3,490 $3,731
Equity-method investments8,123 11,637
Total long-term investments and equity-method investments$11,613 $15,368
Held-to-maturity cash equivalents$250 $207
(a)Represent money market funds primarily invested in U.S. Treasury and government debt.
(b)Represent investments in the life sciences sector.
Debt Securities
Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions:
March 31, 2024December 31, 2023
Gross UnrealizedContractual or Estimated Maturities (in Years)Gross Unrealized
(MILLIONS)Amortized CostGainsLossesFair ValueWithin 1Over 1
to 5Over 5Amortized CostGainsLossesFair Value
Available-for-sale debt securities
Government and agency non-U.S.
$5,414 $2 $(71)$5,345 $5,214 $131 $ $953 $2 $(14)$941
Government and agency U.S.
1,958 1,958 1,958 2,601 2,601
Corporate and other1,057 (6)1,051 1,045 6 1,006 4 (2)1,007
Held-to-maturity debt securities
Time deposits and other
705 705 665 27 13 561 561
Government and agency non-U.S.
100 100 95 4 1 4 4
Total debt securities$9,234 $2 $(78)$9,159 $8,976 $168 $14 $5,126 $6 $(16)$5,115
Any expected credit losses to these portfolios would be immaterial to our financial statements.
Equity Securities
The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:
Three Months Ended
(MILLIONS)March 31,
2024April 2,
2023
Net (gains)/losses recognized during the period on equity securities(a)
$(25)$451
Less: Net (gains)/losses recognized during the period on equity securities sold during the period(214)(33)
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date(b)
$188 $485
(a)Reported in Other (income)/deductions net. See Note 4.
18
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(b)Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of March 31, 2024, there were cumulative impairments and downward adjustments of $293 million and upward adjustments of $212 million. Impairments, downward and upward adjustments were not material to our operations in the first quarters of 2024 and 2023.